Company intelligence / Profile preview

C&Co

San Francisco, California, United States

Ownership: Private
Employees: ~50
Development stage: Other

Overview

C&Co is a clinical-stage biotechnology company focused on developing innovative therapies for oncology and other high-unmet-need therapeutic areas. The company's lead programs utilize small molecule and monoclonal antibody modalities to target key pathways in tumor growth and metastasis, such as VEGFR and EGFR. Currently, C&Co is advancing several candidates through Phase 1 and Phase 2 clinical trials, aiming to provide more effective treatment options for patients with solid tumors. With a robust pipeline and strategic focus on precision medicine, the company is positioned to address complex challenges in cancer care.

Therapeutic areas: Oncology
Modalities: Small moleculeMonoclonal antibody
Industry: Biotech

Beyond the preview

Go deeper on C&Co.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on C&Co.

Explore the full profile